Selskabets formål er markedsføring og salg af lægemidler og helseprodukter samt dermed beslægtet virksomhed.
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2024 | 79.8 mio. | 6.9 mio. | 47.7 mio. | 19.8 mio. | 14 | |
CVR: 39503778
Secondary names: Karo Pharma ApS, Trimb Denmark ApS
Compared to 406 companies in Engroshandel med medicinalvarer og sygeplejeartikler
Comparison is based on industry median values
Karo Healthcare ApS demonstrates a positive financial trajectory, with revenue increasing from 64.3 million DKK in 2023 to 79.8 million DKK in 2024, alongside a notable rise in profit from 4.3 million DKK to 6.9 million DKK. The company's equity has also improved significantly, reaching 19.8 million DKK in 2024, indicating a strong capital position relative to previous years. Despite a slight decline in revenue in 2022 and 2021, the overall trend appears to be growing, suggesting effective management and market positioning within the pharmaceutical and healthcare supplies sector. Key strengths include rising profitability and equity, though ongoing monitoring of margins and potential debt levels is advisable to ensure sustained growth.
AI-generated summary
Companies in the same industry and area
CVR 33671245
CVR 40041796
CVR 43346814
CVR 43605321
CVR 19389006
companydata.dk